More than 2,800 patients got a heart medicine from Cytokinetics by Sept. 30
Cytokinetics (CYTK) reported Q3 2026 earnings, with $47.6M in revenue, driven by $44.5M from MYQORZO sales. Over 2,800 patients received MYQORZO by Sept. 30. The company plans to submit regulatory filings for aficamten in non-obstructive HCM in Q4 2026 and early 2027. Cash reserves were $1.6B, down from $1.7B in Q2 2026. Net loss was $190.1M, or $1.37 per share.
How this was made
The 30-second read
Why it matters
The earnings release introduces new financial metrics and trial milestones that may influence investor sentiment.
Market read
First-time disclosure of Q3 results and trial updates, relevant for biotech investors.
What to watch
Potential future revenue from European launches and upcoming supplemental NDA filings.
Background
Cytokinetics provided its Q3 2026 earnings and operational updates, highlighting product launch progress.
Ticker impact
Q3 2026 financial results disclosed for the first time, including $47.6M revenue and $190.1M net loss.
downward pressure as investors digest higher loss and elevated expenses
The release shows a larger net loss than prior year and high SG&A, suggesting cash burn concerns.
Market effects
Biotech and specialty cardiology sector may see heightened scrutiny on cash burn and trial progress.
U.S. biotech investors may adjust exposure; limited impact outside the sector.
Modest, primarily affecting CYTK and peers tracking cardiac myosin inhibitors.
Counterpoint
Despite the loss, the expanding patient base and upcoming regulatory filings could support upside.
Key entities
- companyCytokinetics, Inc.
US-listed biotech developing cardiac myosin inhibitors.
